Treatment with growth hormone for eight years led to a lower spine curvature in children with Prader-Willi syndrome (PWS) who developed scoliosis, a preliminary Dutch study reports. The research, “Effects of eight years growth hormone treatment on the onset and progression of scoliosis in children with Prader-Willi syndrome,”…
News
Supervised exercise sessions at home are an effective strategy to improve the levels of physical activity and walking capacity among women with Prader-Willi syndrome (PWS), a new study suggests. The research, “Increasing physical activity in adult women with Prader–Willi syndrome: A transferability study,” was published in the Journal…
The gut microbiome — the microbial community in the gut — of people with Prader-Willi syndrome (PWS) is more diverse than those of individuals with common obesity, and it may protect them from insulin resistance, a condition that often precedes type 2 diabetes, a study reports. The study, “…
People with Prader-Willi syndrome (PWS) have difficulty recognizing negative emotions throughout their lives, often confusing sadness with anger, a study reports. In addition, they have trouble understanding the sincere intentions of others, the findings also showed. The study, “Profiles and Trajectories of Impaired Social Cognition in People with…
Caregivers of young children with Prader-Willi syndrome (PWS) report low quality of life, highlighting the need for additional support systems for these families, a new Chinese study has found. The findings also indicate that caregivers of PWS children with poor social skills or other symptoms such as obesity or…
Recombinant growth hormones Eutropin and Genotropin were found to produce similar improvements in growth, body fat composition, and motor and cognitive development in infants with Prader-Willi syndrome (PWS), a study has found. The results also suggest that Eutropin is a safe growth hormone to treat infants with PWS.
The birth of children in the U.S. with Prader-Willi syndrome (PWS) — a rare disease caused by deletions in the chromosome 15q11-q13 region of the father — does not follow a seasonal pattern, a study found. The results suggest that seasonal exposure to chromosome-damaging agents…
News
Research Supported by PWS Foundation to Examine Cause of Behavioral Problems, Possible Treatment
A grant winner’s research may help to advance a possible treatment of behavioral problems like temper outbursts in Prader-Willi syndrome patients. The treatment, an approved medication but not for PWS, works by modulating the levels of a neurotransmitter that might restore a balance in brain signals. …
The Data Safety Monitoring Board (DSMB) has recommended, for the second time, the continuation of Soleno Therapeutics’ Phase 3 DESTINY PWS clinical trial evaluating the effects of diazoxide choline controlled release (DCCR) for treating children and adults with Prader-Willi syndrome (PWS). DCCR is…
Prader-Willi syndrome (PWS) has been given its own unique code by the National Center for Health Statistics (NCHS), which will make it easier to track accurate data on medical care and clinical outcomes of people with the disease. The NCHS is responsible for assigning different diseases with ICD-10…
Recent Posts
- PWS doctors skip sleep studies for early growth hormone therapy
- We all ‘come out’ in our own ways, including PWS families
- Testosterone therapy aids bone health in PWS, with low behavior impact
- Why common illnesses can look different with Prader-Willi syndrome
- Getting away is hard for couples raising a medically complex child
- Interdisciplinary inpatient care may boost outcomes in PWS patients
- Staying present is a challenge when you know what PWS might bring next
- More tolerable PWS hunger therapies slated for new human trials next year
- What looked like allergies was actually a PWS symptom we didn’t know about
- Genetic subtype may affect duration of low oxygen in Prader-Willi syndrome